CSL112 (Apolipoprotein A-Ⅰ) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-ⅠEvent ReducinGInIschemicSyndromes Ⅱ (AEGIS-ⅡTrial): Primary Trial Results CSL112(载脂蛋白A-1)输注与急性...
清华大学附属北京清华长庚医院心血管内科张萍教授团队将在现场为您带来实时系列报道,敬请关注。 CSL112 (Apolipoprotein A-Ⅰ) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-ⅠEvent ReducinGInIschemicSyndromes Ⅱ (AEGIS-ⅡTrial): Primary Trial Results CSL112(载脂蛋白A-...
2.https://newsroom.csl.com/2024-02-11-CSL-Announces-Top-line-Results-from-the-Phase-3-AEGIS-II-Trial-Evaluating-the-Efficacy-and-Safety-of-CSL112-apolipoprotein-A-I-human 3.C. Michael Gibson, et al. Rationale...
RESULTS. CSL112 infusion increased AER dose-dependently, peaking at 2h (end of infusion) and returning to baseline by 24h post infusion (Figure 1). AER was significantly correlated with CEC (total, ABCA1 dependent and independent), HDL-cholesterol, apoA-I and phosphatidylcholine across all ...
Global biotechnology leader CSL announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an ac...
CSL112 administration resulted in increases in ApoA-I and cholesterol efflux similar to those observed in patients with AMI and normal renal function or stage 2 CKD enrolled in the ApoA-I Event Reducing in Ischemic Syndromes I trial.These results demonstrate the acceptable safety of the 6-g ...
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized... Background CSL112 is a new formulation of human apolipoprotein A???I (apoA???I) being developed to reduce cardiovascular events following ac...
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a studydoi:10.1007/s11239-018-1644-zAtherosclerosis?Dualantiplatelettherapy?High-densitylipoprotein?Clinicaltrials?
https://doi.org/10.1161/CIRCULATIONAHA.116.025687 2.https://newsroom.csl.com/2024-02-11-CSL-Announces-Top-line-Results-from-the-Phase-3-AEGIS-II-Trial-Evaluating-the-Efficacy-and-Safety-of-CSL112-apolipoprotein-A-I...